After Plunging 33.8% in 4 Weeks, Here's Why the Trend Might Reverse for Twist Bioscience (TWST)

Twist Bioscience (TWST) stock has declined 33.8% over the past four weeks, but technical and fundamental indicators suggest a potential near-term reversal. Its Relative Strength Index (RSI) of 23.07 places it in oversold territory, while sell-side analysts have raised consensus EPS estimates by 4.3% in the last 30 days. Furthermore, TWST holds a Zacks Rank #2 (Buy), signaling a possible rebound driven by improving earnings outlooks.

Analysis

Twist Bioscience (TWST) has experienced significant selling pressure, resulting in a 33.8% price decline over the past four weeks. This has pushed the stock into technically oversold territory, as indicated by a Relative Strength Index (RSI) of 23.07. While technical signals alone are not conclusive, this condition is coupled with positive fundamental developments. Sell-side analysts have upwardly revised the consensus EPS estimate for the current year by 4.3% over the last 30 days, suggesting an improving earnings outlook. This combination of a potential exhaustion of selling pressure and strengthening analyst sentiment is further reinforced by the stock's Zacks Rank #2 (Buy), which is based on trends in earnings estimate revisions. The convergence of these technical and fundamental factors suggests a potential for a near-term price reversal as the market may begin to price in the improved earnings expectations.

Key Decisions for Investors

• Investors with a higher risk tolerance could view the combination of a 23.07 RSI and a 4.3% upward EPS estimate revision as a tactical opportunity to initiate a long position, anticipating a mean-reversion rally.
• It is prudent to monitor for confirmation of a price-based reversal, as the recent 33.8% decline indicates strong negative momentum that may not be immediately overcome by technical signals alone.
• The positive shift in analyst sentiment, reflected in the earnings estimate increase and Zacks Rank #2, should be considered a primary driver, and investors should watch for continued positive revisions as a key fundamental catalyst.